About Tolero Pharma
Tolero Pharma is a Healthcare company based in Lehi (United States) founded in 2011, and was acquired by Sumitomo Dainippon Pharma in December 2016. Therapeutics for cancer and blood disorders are developed. Tolero Pharma has raised $48.23 million across 4 funding rounds from investors including Alger and Sumitomo Dainippon Pharma. The company has 17 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Tolero Pharma was founded in 2011 and is based in Lehi, United States. Operations focus on the development of therapeutics targeting biological drivers of blood disorders, including leukemias and anemia. The pipeline features an immunotherapeutic cancer vaccine as the lead candidate, along with inhibitors for AXL, CDK9, ALK2, PIM, and BTK. Efforts center on oncology within the biopharmaceutical sector.
- Headquarters Lehi, United States
- Employees 17
- Stage Acquired
- SectorsHealthcare
- Website toleropharma.com
- Social LinkedIn Facebook
- Acquired by Sumitomo Dainippon Pharma (Dec 2016)
- Total Equity Funding$48.23M (USD)
in 4 rounds
- Latest Funding Round$8.2M (USD), Series B
Dec 2014
- InvestorsAlger
& 1 more
- Employee Count17
- Acquired bySumitomo Dainippon Pharma
(Dec 2016)
Funding Insights of Tolero Pharma
Tolero Pharma has successfully raised a total of $48.23M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $8.2 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $48.23M
- Total Rounds 4
- Last Round Series B β $8.2M
- First Round $3.33M
(Jul 2012)
- Investors Count 1
All 4 funding rounds of Tolero Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Tolero Pharma
Tolero Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Alger and Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
ESG investments are managed by this venture capital firm. | 1964 | alger.com | New York, United States | |
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured. | 1897 | ds-pharma.com | Osaka, Japan |
Investor details for Tolero Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Tolero Pharma
4 dated milestones of Tolero Pharma across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Tolero Pharma is founded.
- Funding First funding round of $3.3M.
- Funding Latest funding round, Series B, of $8.2M.
- Exit Acquired by Sumitomo Dainippon Pharma.
Competitors of Tolero Pharma
Tolero Pharma has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Tolero Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Tolero Pharma (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tolero Pharma
Complete news archive for Tolero Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tolero Pharma
Tolero Pharma was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Tolero Pharma is headquartered in Lehi, United States. It is registered at Lehi, Utah, United States.
Tolero Pharma is a funded company, having raised a total of $48.23M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.33M, raised on Jul 2012.
Tolero Pharma has 17 employees.
Tolero Pharma was founded in 2011 and is based in Lehi, United States. Operations focus on the development of therapeutics targeting biological drivers of blood disorders, including leukemias and anemia. The pipeline features an immunotherapeutic cancer vaccine as the lead candidate, along with inhibitors for AXL, CDK9, ALK2, PIM, and BTK. Efforts center on oncology within the biopharmaceutical sector.
Tolero Pharma has 2 investors. Key investors include Alger, and Sumitomo Dainippon Pharma.
Yes. Tolero Pharma was acquired by Sumitomo Dainippon Pharma in December 2016.

